Drugs / GC5131
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04555148 | Sep 2020 → Jan 2021 | COVID-19 | Green Cross Corporation | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-12-17 | Kang Stem Biotech Co., Ltd. | Regulatory [데일리팜] 치료제 없는 코로나, 긴급승인 41건...'GC5131' 22건 최다 (20.12.17) kangstem.com ↗
치료제 없는 코로나, 긴급승인 41건...'GC5131' 22건 최다 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-12-17 | Kang Stem Biotech Co., Ltd. | [데일리팜] 치료제 없는 코로나, 긴급승인 41건...'GC5131' 22건 최다 (20.12.17) kangstem.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GC5131 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04555148 ↗ |
| Modality | Protein / enzyme biologic | “Hyper-Ig (Hyper-immunoglobulin) GC5131” NCT04555148 ↗ |